EUVIMEDEUVIMED entdecken
Open Access

Diagnostic and prognostic utility of PSMA ‐ PET / CT in node‐metastatic prostate cancer

Nicholas A Pickersgill, Rebecca Yu, Emily A Vertosick, Sean A Fletcher, Nicole Liso, Jonas Kluckert, Oguz Akin, Behfar Ehdaie iD, Vincent P Laudone, James A Eastham, Andrew J Vickers iD, Karim A Touijer und 1 weitere

BJU International · 2026-08 · 138 (2) · 250-256

DOI: 10.1111/bju.70280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, online erschienen am 30.04.2026. Verfasst von Nicholas A Pickersgill und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Lymphatic Metastasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Sidney Kimmel Center for Prostate and Urologic Cancers at MSKCC and NIH/NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To measure the sensitivity of prostate‐specific membrane antigen‐positron emission tomography/computed tomography (PSMA‐PET/CT) for detecting lymph node involvement (LNI) in patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (PLND) and to evaluate whether PSMA nodal status independently predicts oncological outcomes. Patients and Methods We identified patients with localised or locoregional prostate cancer who underwent PSMA‐PET/CT followed by RP (2021–2024) at a high‐volume centre and had pathologically confirmed LNI (pN1) on PLND. We evaluated the sensitivity of PSMA‐PET/CT for detecting pN1 disease. Associations between PSMA‐PET/CT and biochemical recurrence (BCR), any radiographic recurrence, and distant recurrence were evaluated using Cox regression models.

Results

Overall, PSMA‐PET/CT detected LNI in 24 of 79 patients with pN1 disease, a sensitivity of 30% (95% confidence interval [CI] 21–42%). PSMA‐positive nodal disease (clinical N1 [cN1]) was significantly associated with BCR (hazard ratio [HR] 2.34, 95% CI 1.26–4.36; P = 0.009), radiographic recurrence (HR 4.23, 95% CI 1.86–9.58; P < 0.001), and distant radiographic recurrence (HR 5.81, 95% CI 1.79–18.8; P = 0.002). The 1‐year risk of BCR approached 90% for those with cN1 disease. Median metastatic focus size was larger in cN1 vs cN0 patients (1.1 vs 0.3 cm; P < 0.001). Limitations include relatively short follow‐up.

Conclusions

Due to low sensitivity, PSMA‐PET/CT without evidence of nodal disease does not obviate the need for PLND. However, PSMA‐avid nodal disease portends a nearly inevitable short interval recurrence and radiographic progression, supporting treatment intensification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron Emission Tomography Computed TomographyLymphatic MetastasisHumansMalePrognosisProstatectomyAgedMiddle AgedLymph Node ExcisionAntigens, SurfaceNeoplasm Recurrence, LocalRetrospective StudiesSensitivity and Specificity

Stichwörter der Autor:innen

biochemical recurrencelymph node metastasisprostate cancerprostate‐specific membrane antigen‐positron emission tomography/computed tomogr…radical prostatectomy

Substanzen

Antigens, Surface

Autor:innen und Institutionen

  • Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: Behfar Ehdaie, Andrew J Vickers, Christoper D Gaffney

Förderung

  • NCI NIH HHS
  • Sidney Kimmel Center for Prostate and Urologic Cancers at MSKCC and NIH/NCI

Zitieren

APA

Pickersgill, N. A., Yu, R., Vertosick, E. A., Fletcher, S. A., Liso, N., Kluckert, J., Akin, O., Ehdaie, B., Laudone, V. P., Eastham, J. A., Vickers, A. J., Touijer, K. A., & Gaffney, C. D. (2026). Diagnostic and prognostic utility of PSMA ‐ PET / CT in node‐metastatic prostate cancer. BJU International, 138(2), 250-256. https://doi.org/10.1111/bju.70280

Vancouver

Pickersgill NA, Yu R, Vertosick EA, Fletcher SA, Liso N, Kluckert J, et al. Diagnostic and prognostic utility of PSMA ‐ PET / CT in node‐metastatic prostate cancer. BJU International. 2026;138(2):250-256. doi:10.1111/bju.70280

BibTeX
@article{Pickersgill2026,
  author = {Pickersgill, Nicholas A and Yu, Rebecca and Vertosick, Emily A and Fletcher, Sean A and Liso, Nicole and Kluckert, Jonas and Akin, Oguz and Ehdaie, Behfar and Laudone, Vincent P and Eastham, James A and Vickers, Andrew J and Touijer, Karim A and Gaffney, Christoper D},
  title = {Diagnostic and prognostic utility of PSMA ‐ PET / CT in node‐metastatic prostate cancer},
  journal = {BJU International},
  year = {2026},
  volume = {138},
  number = {2},
  pages = {250--256},
  doi = {10.1111/bju.70280}
}
Kostenlos starten →